Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Gastroenterol ; 48(2): 269-76, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22825550

ABSTRACT

BACKGROUND: Nocturnal administration of branched-chain amino acid (BCAA) granules improves serum albumin levels in patients with cirrhosis. However, it is unclear whether or not this administration method can improve the patients' quality of life (QOL). In this study, we aimed to investigate the efficacy of BCAA granules, given nocturnally, in improving QOL in these patients. METHODS: We performed a multicenter, randomized controlled trial examining the comparative effects of BCAA granules given orally for 3 months with daytime or nocturnal administration in patients with compensated cirrhosis. Health-related QOL was measured by a Japanese version of the questionnaire on subjective and objective symptoms, and the Short Form-8 (SF-8) questionnaire. RESULTS: Twenty-one patients received BCAA granules three times a day (one sachet after each meal: the daytime group), and 16 patients received the granules twice a day (one sachet after breakfast, and two sachets before bedtime: the nocturnal group). Baseline characteristics did not differ between the groups (whole cohort: Child-Pugh grade A/B, 21/16; mean age, 68.2 years). There was no significant difference in any of the subjects revealed by the questionnaire regarding subjective or objective symptoms, or by the SF-8 between the daytime group and the nocturnal group after 3 months of treatment. The daytime group showed a significant effect on general health, vitality, social functioning, mental health, and role emotional as revealed on the SF-8. Conversely, the nocturnal group exhibited a significant decrease in the occurrence of muscle cramps in the legs (P = 0.014) and significantly improved Fisher's ratio after 3 months (P = 0.04). CONCLUSIONS: Nocturnal administration of BCAA granules in patients with cirrhosis reduced the occurrence of muscle cramps in the leg but did not improve the patients' QOL.


Subject(s)
Amino Acids, Branched-Chain/administration & dosage , Liver Cirrhosis/drug therapy , Quality of Life , Administration, Oral , Adult , Aged , Aged, 80 and over , Amino Acids, Branched-Chain/adverse effects , Amino Acids, Branched-Chain/therapeutic use , Biomarkers/blood , Carcinoma, Hepatocellular/etiology , Drug Administration Schedule , Esophageal and Gastric Varices/etiology , Female , Follow-Up Studies , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/complications , Liver Cirrhosis/rehabilitation , Liver Neoplasms/etiology , Male , Medication Adherence , Middle Aged , Psychometrics , Treatment Outcome
2.
Nihon Shokakibyo Gakkai Zasshi ; 104(10): 1486-91, 2007 Oct.
Article in Japanese | MEDLINE | ID: mdl-17917396

ABSTRACT

A 64-year-old woman who admitted because of abdominal pain and ascites. She was diagnosed as having systemic lupus erythematosus (SLE) and lupus peritonitis based on anti ds-DNA antibody, ANA positive, serositis and renal dysfunction. She was successfully treated by intravenous pulse therapy with methylprednisolone, but her enteritis recurred after switching to oral administration. She recovered following pulse therapy with methylprednisolone and extracorporeal apheresis. This case was characterized by a rather old age of onset and the peculiar initial symptoms of peritonitis.


Subject(s)
Lupus Erythematosus, Systemic/complications , Peritonitis/etiology , Antibodies, Antinuclear/blood , Biomarkers , Blood Component Removal , DNA/immunology , Female , Humans , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/therapy , Methylprednisolone/administration & dosage , Middle Aged , Peritonitis/diagnosis , Peritonitis/therapy , Pulse Therapy, Drug , Treatment Outcome
3.
J Biol Chem ; 278(10): 8395-400, 2003 Mar 07.
Article in English | MEDLINE | ID: mdl-12496241

ABSTRACT

Membrane-associated guanylate kinase homologues (MAGUKs) are generally found under the plasma membrane of cell-cell contact sites and function as scaffolding proteins by linking cytoskeletal and signaling molecules to transmembrane receptors. The correct targeting of MAGUKs is essential for their receptor-clustering function; however, the molecular mechanism of their intracellular transport is unknown. Here, we show that the guanylate kinase-like domain of human discs large protein binds directly within the amino acids 607-831 of the stalk domain of GAKIN, a kinesin-like protein of broad distribution. The primary structure of the binding segment, termed MAGUK binding stalk domain, is conserved in Drosophila kinesin-73 and some other motor and non-motor proteins. This stalk segment is not found in GKAP, a synaptic protein that interacts with the guanylate kinase-like domain, and unlike GKAP, the binding of GAKIN is not regulated by the intramolecular interactions within the discs large protein. The recombinant motor domain of GAKIN is an active microtubule-stimulated ATPase with k(cat) = 45 s(-1), K(0.5 (MT)) = 0.1 microm. Overexpression of green fluorescent protein-fused GAKIN in Madin-Darby canine kidney epithelial cells induced long projections with both GAKIN and endogenous discs large accumulating at the tip of these projections. Importantly, the accumulation of endogenous discs large was eliminated when a mutant GAKIN lacking its motor domain was overexpressed under similar conditions. Taken together, our results indicate that discs large is a cargo molecule of GAKIN and suggest a mechanism for intracellular trafficking of MAGUK-laden vesicles to specialized membrane sites in mammalian cells.


Subject(s)
Kinesins/metabolism , Nucleoside-Phosphate Kinase/metabolism , Adenosine Triphosphatases/metabolism , Binding, Competitive , Electrophoresis, Polyacrylamide Gel , Guanylate Kinases , Humans , Jurkat Cells , Protein Binding , Protein Transport
SELECTION OF CITATIONS
SEARCH DETAIL
...